Schulze S, Mennel S
Ophthalmology, University Hospital Giessen and Marburg GmbH, Robert-Koch-Strasse 4, Marburg.
Klin Monbl Augenheilkd. 2007 Oct;224(10):787-90. doi: 10.1055/s-2007-963491.
Idiopathic juxtafoveolar retinal telangiectasis presents areas of occult capillary telangiectasis involving the temporal half of the fovea. Its treatment by laser photocoagulation, photodynamic therapy or intravitreal injection of triamcinolone is unsatisfying concerning visual acuity. Recently it has been demonstrated that intravitreal bevacizumab injection could be successful in the treatment of choroidal neovascularisations secondary to ARMD. The principle of this treatment may be successful for the treatment of idiopathic juxtafoveolar retinal telangiectasis as well.
We report about 3 cases treated with three monthly intravitreal injections of bevacizumab. Fluorescein angiographies and OCT measurements of retinal thickness were performed.
The mean increase of VA was 2 visual steps. In two cases an increase of 5 and 1 visual steps, respectively, could be determined, in the other case no increase was found. The mean retinal thickness decreased from 300 microns to 287 microns.
According to our results bevacizumab seems to be less suitable for treatment of idiopathic juxtafoveolar retinal telangiectasis because only a small decrease of retinal thickness can be observed.
特发性黄斑旁视网膜毛细血管扩张症表现为累及黄斑颞侧半的隐匿性毛细血管扩张区域。其通过激光光凝、光动力疗法或玻璃体内注射曲安奈德进行治疗，在视力改善方面并不令人满意。最近有研究表明，玻璃体内注射贝伐单抗可成功治疗湿性年龄相关性黄斑变性继发的脉络膜新生血管。这种治疗原则可能对特发性黄斑旁视网膜毛细血管扩张症的治疗也有效。
我们报告了3例每3个月接受1次玻璃体内注射贝伐单抗治疗的患者。进行了荧光素血管造影和视网膜厚度的光学相干断层扫描测量。
平均视力提高了2行。其中2例分别提高了5行和1行，另一例视力无提高。平均视网膜厚度从300微米降至287微米。
根据我们的结果，贝伐单抗似乎不太适合治疗特发性黄斑旁视网膜毛细血管扩张症，因为只能观察到视网膜厚度有小幅下降。
Zotero 插件